What is Semaglutide?
Semaglutide is a long-acting receptor agonist that shares 94% sequence homology with native human
Semaglutide — long-acting GLP-1 receptor agonist
In short
Long-acting GLP-1 receptor agonist studied in large-scale clinical models of obesity and glucose homeostasis.
Overview
Semaglutide is a long-acting receptor agonist that shares 94% sequence homology with native human
Semaglutide binds to and activates the receptor (GLP-1R) on pancreatic β-cells, hypothalamic neurons, and gastrointestinal smooth muscle. Receptor activation potentiates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and produces central appetite suppression via hypothalamic signaling. Unlike sulfonylureas, the insulinotropic effect is strictly glucose-dependent — minimizing hypoglycemia risk in research models with intact pancreatic function.
Molecular information
First-order decay curve at 168.0h half-life from literature. Educational only.
Гастроинтестиналните събития — гадене, повръщане, диария, запек — са най-често съобщаваните нежелани реакции в клиничните изследвания. Острият панкреатит е разпознат сигнал в дългосрочни проучвания и налага прекратяване при съмнение. Тиреоидни C-клетъчни тумори са наблюдавани в гризачни модели; човешката релевантност остава под изследване. Употребата е противопоказана в модели с лична или фамилна анамнеза за медуларен карцином на щитовидната жлеза или синдром на множествена ендокринна неоплазия тип 2.
5 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Information about Semaglutide is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.